Oculus Innovative Sciences has entered into an agreement with OroScience granting Oroscience exclusive rights to market Microcyn-based oral products in the U.S., Canada, and Europe in exchange for providing Oculus with a significant percentage of those revenues.
OroScience will support all regulatory, clinical, sales, and marketing related to the Microcyn-based professional oral care products, with the first product launch anticipated in 2010, according to the companies.
"We've identified a number of professional dental and oral care product opportunities for the Microcyn technology, with one Microcyn-based product opportunity having an estimated addressable U.S. market on the order of $500 million," said Mark Fontenot, CEO of OroScience, in a pressrelease. "We believe our planned suite of Microcyn-based products will bring significant patient benefit for several important conditions such as oral manifestations of diabetes and oral mucositis, secondary to chemotherapy and/or radiotherapy. Our intent is to utilize our broad reach of national distribution partners to achieve timely and ubiquitous distribution."
The Microcyn Technology platform is intended to help prevent and treat infections in chronic and acute wounds, enabling the creation of a biocompatible solution containing active oxychlorine compounds. The solutions derived from the shelf-stable Microcyn Technology platform have demonstrated the ability to treat a wide range of pathogens in various research and investigational studies, according to Oculus.
Copyright © 2009 DrBicuspid.com
